Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of the transaction, the resulting entity will continue the business of Atriva Therapeutics. Shareholders of Atriva will receive not less than 75% of the securities of the resulting issuer, with the current shareholders of Biocure Technology holding the remainder. The transaction is subject to various terms and conditions, including
EQS-News: Atriva Therapeutics GmbH / Key word(s): Letter of Intent Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology 18.09.2023 / 15:05 CET/CEST The issuer is solely responsible for the content of this announcement. Atriva Therapeut.
VANCOUVER, BC, Sept. 14, 2023 /CNW/ - The following issues have been halted by CIRO: Company: Biocure Technology Inc. CSE Symbol: CURE All Issues: Yes Reason: Pending News Halt Time (ET): 4:26 PM CIRO can make a
Biocure Technology Inc : BioCure Technology Inc Lists on the Frankfurt Stock Exchange and Completion of Issuer Sponsored Research Report finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.